54528-22-2Relevant articles and documents
Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties
Gunzner-Toste, Janet,Zhao, Guiling,Bauer, Paul,Baumeister, Timm,Buckmelter, Alexandre J.,Caligiuri, Maureen,Clodfelter, Karl H.,Fu, Bang,Han, Bingsong,Ho, Yen-Ching,Kley, Nikolai,Liang, Xiaorong,Liederer, Bianca M.,Lin, Jian,Mukadam, Sophie,O'Brien, Thomas,Oh, Angela,Reynolds, Dominic J.,Sharma, Geeta,Skelton, Nicholas,Smith, Chase C.,Sodhi, Jasleen,Wang, Weiru,Wang, Zhongguo,Xiao, Yang,Yuen, Po-Wai,Zak, Mark,Zhang, Lei,Zheng, Xiaozhang,Bair, Kenneth W.,Dragovich, Peter S.
, p. 3531 - 3538 (2013/07/28)
Potent, reversible inhibition of the cytochrome P450 CYP2C9 isoform was observed in a series of urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. This unwanted property was successfully removed from the described inhibitors throug
4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER
-
Page/Page column 230-231, (2012/03/26)
The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An embodiment of the invention is the provision of a compound of Formula IIIA.
